Spesolimab (SPEVIGO)
IL-36 receptor antibody for generalized pustular psoriasis flares
About This Treatment
Spesolimab blocks the IL-36 receptor and is used for generalized pustular psoriasis flares, a severe systemic pustular disease. This is a medical dermatology plan rather than an aesthetic treatment.
Diagnosis and systemic monitoring in specialist care are essential.
Mechanism of Action
IL-36 receptor blockade suppresses neutrophilic inflammation, pustule formation and systemic inflammatory flares.
Indications
Expected Results
Effisayil-1 showed higher week-1 pustule clearance versus placebo, supporting rapid flare control.
Clinical Evidence
Risks & Side Effects
Infections, hypersensitivity, infusion reactions, fatigue and nausea may occur. GPP itself requires systemic assessment and often inpatient-level care.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition